Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Marina Garassino
The University of Chicago, Chicago, USA
Prof. Marina Garassino is a professor of medicine in the Department of Medicine, Section of Hematology-Oncology, at The University of Chicago in the USA. Before assuming this role, she served as chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori in Milan, Italy, until February 2021. In this capacity, she led the clinical and translational research strategy for advanced and locally advanced non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and thymic malignancies. read more
Prof. Garassino earned her medical degree and further specialization in medical oncology from the University of Milan, graduating (110/110 cum laude) in 1995. She completed her training through an ESMO Clinical Fellowship at The Christie NHS Foundation Trust in Manchester, UK, in 2009.
As a medical oncologist, Prof. Garassino has focused her research on precision medicine and immuno-oncology, with an emphasis on developing new drugs, therapeutic strategies and biomarkers. She previously served as chair of TYME, the Italian research network for thymic malignancies, and has contributed to over 260 peer-reviewed publications, including first- and last-author papers in The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology.
She has also delivered numerous presentations at major international conferences, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the European CanCer Organization (ECCO), the World Conference on Lung Cancer (WCLC) and the American Association for Cancer Research (AACR). Over the past 5 years, she has secured multiple research grants from organizations such as the Italian Medicines Agency (AIFA), AIRC Foundation for Cancer Research, ERA-NET TRANSCAN, The Guido Berlucchi Foundation, Horizon 2020 and industry-sponsored trials.
She has been an active member of the European Medicines Agency’s (EMA) Scientific Advisory Group (SAG) and has served on the ESMO Council as chair of National Societies. From 2011 to 2017, she was the ESMO Italian national representative and continues to contribute to several ESMO task forces, including the Public Policy Extended Committee, the Press Committee and Women for Oncology. Additionally, she has served as ASCO faculty for the Lung Cancer Track.
Prof. Garassino is also the founder and honorary president of Women for Oncology Italy.
Prof. Marina Garassino discloses: Speaker’s bureau and advisory panel fees from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IO Biotech, Janssen Pharmaceuticals, Merck & Co, Mirati Therapeutics, Natera, Novocure, Nuvation, Pfizer, Regeneron, Revolution Medicines, Roche and Takeda. Grant/research support from AIFA, AIRC, Horizon 2020, Italian MoH and TRANSCAN.
Prof. Jarushka Naidoo
Beaumont RCSI Cancer Centre, Dublin, Ireland
Prof. Jarushka Naidoo is a consultant medical oncologist at the Beaumont Hospital Dublin and a full professor at the Royal College of Surgeons in Ireland (RCSI). Before joining RCSI in late 2020, she was an assistant professor of medical oncology and a lung cancer specialist at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in the USA. She currently holds the position of adjunct assistant professor of oncology at Johns Hopkins University. She also serves as the national lung cancer lead for Cancer Trials Ireland. read more
Prof. Naidoo received her medical degree from Trinity College Dublin and completed her internal medicine and medical oncology training in Ireland. This was followed by an advanced medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York, USA, before joining the faculty at Johns Hopkins and then returning to Ireland.
Prof. Naidoo is an internationally recognized leader in immunotherapy for lung cancer, melanoma and immune-related toxicity. She contributes to several international guideline panels, including those for the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). She is an experienced clinical trialist, having developed and completed several investigator-initiated, industry-funded, and cooperative group clinical trials.
Prof. Naidoo has received numerous grants, including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), the Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2 programme. She is deeply committed to education and training in oncology and has mentored numerous early-career physicians, fellows and medical students, whose achievements include high-level publications and young investigator awards.
Prof. Jarushka Naidoo discloses: Advisory board or panel fees from AbbVie, Amgen, Arcus Biosciences, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Elevation Oncology, Mirati Therapeutics, Novartis, Oxford Therapeutics, Pfizer, Regeneron, Roche/Genentech, Summit Therapeutics, Takeda and Zymeworks. Grant/research support from Amgen, Arcus Biosciences, Bristol Myers Squibb, Daiichi Sankyo, Mirati Therapeutics, Novartis and Roche/Genentech.
Prof. David Planchard
Institut Gustave Roussy, Villejuif, France
Prof. David Planchard is a thoracic oncologist and head of the Thoracic Group at Institut Gustave Roussy (IGR) in Villejuif, France. With over 20 years of experience, his research has focused on immunotherapy, genomic analysis, biomarkers, and targeted treatments for lung cancer. He has been involved in more than 300 phase I, II and III clinical trials and has authored over 270 publications. Since 2020, he has been recognized as a Clarivate ‘Highly Cited Researcher’. read more
Prof. Planchard has been directly involved in clinical trial design, serving as the international coordinating investigator for multiple trials in the field of thoracic tumours to develop a long-term research strategy based on molecular screening.
He has contributed to the latest European recommendations for the management of metastatic non-small cell lung cancer (European Society for Medical Oncology [ESMO] guidelines) and is an active speaker at leading national and international conferences, including ESMO, the European Lung Cancer Congress (ELCC), the American Society of Clinical Oncology (ASCO) and the World Conference on Lung Cancer (WCLC).
Prof. David Planchard discloses: Advisory board or panel fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharmaceuticals, Merck, Mirati Therapeutics, Novartis, Pfizer, Pierre Fabre, Roche, Seagen and Takeda. Clinical trials research as principal or co-investigator (institutional financial interests) fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Janssen Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Novartis, Novocure, Pfizer, Pierre Fabre, Roche, Sanofi-Aventis, Seagen, Taiho Pharma and Takeda.
